Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

BACKGROUND: Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). Palbocicl...

詳細記述

保存先:
書誌詳細
出版年:Breast Cancer Res
主要な著者: Darrigues, Lauren, Pierga, Jean-Yves, Bernard-Tessier, Alice, Bièche, Ivan, Silveira, Amanda Bartolini, Michel, Marc, Loirat, Delphine, Cottu, Paul, Cabel, Luc, Dubot, Coraline, Geiss, Romain, Ricci, Francesco, Vincent-Salomon, Anne, Proudhon, Charlotte, Bidard, François-Clément
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2021
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7937332/
https://ncbi.nlm.nih.gov/pubmed/33676547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-021-01411-0
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料